Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA

Molecular Pharmacology

Volumn 54, Issue 5, 1998, Pages 770-777

  Woynarowski, Jan M ^a   Chapman, William G ^a   Napier, Cheryl ^a   Herzig, Maryanne C S ^a   Juniewicz, Paul ^b  

^a CTRC Institute for Drug Development   (United States)

^b Sanofi Synthelabo Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLOBIN; CELL DNA; CISPLATIN; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MITOCHONDRIAL DNA; MYC PROTEIN; OXALIPLATIN; VIRUS DNA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DNA ADDUCT; DNA SEQUENCE; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SIMIAN VIRUS 40;

EID: 0031782847     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.54.5.770     Document Type: Article

References (35)

1. Arnould R, Dubois J, Abikhalil F, Libert A, Ghanem G, Atassi G, Hanocq M, and Lejeune FJ (1990) Comparison of two cytotoxicity assays - tetrazolium derivative reduction (MTT) and tritiated thymidine uptake - on three malignant mouse cell lines using chemotherapeutic agents and investigational drugs. Anticancer Res 10:145-154.
2. Blommaert FA, van Dijk-Knijnenburg HC, Dijt FJ, den Engelse L, Baan RA, Berends F, and Fichtinger-Schepman AM (1995) Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 34:8474-80.
3. Boudny V, Vrana O, Gaucheron F, Kleinwachter V, Leng M, and Brabec V (1992) Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. Nucleic Acids Res 20:267-272.
4. Bubley GJ, Ogata GK, Dupuis NP, and Teicher BA (1994) Detection of sequence-specific antitumor alkylating agent DNA damage from cells treated in culture and from a patient. Cancer Res 54:6325-6329.
5. Chaney S (1995) The chemistry and biology of platinum complexes with the 1,2-diaminocycloxane carrier ligand. Int J Oncol 6:1291-1305.
6. Christian MC (1992) The current status of new platinum analogs. Semin Oncol 19:720-733.
7. Daoud SS, Clements MK, and Small CL (1995) Polymerase chain reaction analysis of cisplatin-induced mitochondrial DNA damage in human ovarian carcinoma cells. Anti-Cancer Drugs 6:405-412.
8. Faivre S and Woynarowski JM (1998) Oxaliplatin effects on DNA integrity and apoptosis induction in human tumor cells (abstract). Proc Am Assoc Cancer Res 39:158.
9. Hemminki K and Thilly WG (1988) Binding of cisplatin to specific sequences of human DNA in vitro. Mutat Res 202:133-138.
10. Hoffmann JS, Johnson NP, and Villani G (1989) Conversion of monofunctional DNA adducts of cis-diamminedichloroplatinum (II) to bifunctional lesions: effect on the in vitro replication of single-stranded DNA by Escherichia coli DNA polymerase I and eukaryotic DNA polymerases alpha. J Biol Chem 264:15130-15135.
11. Inagaki K and Sawaki K (1995) Reaction of (1R,2S,3S)-3-methylcyclohexanediamineplatinum(II) with DNA: isolation and characterization of the platinum-nucleotide adducts by means of HPLC and NMR spectroscopy. Chem Pharmacol Bull 43:183-188.
12. Jennerwein MM and Eastman A (1991) A polymerase chain reaction-based method to detect cisplatin adducts in specific genes. Nucleic Acids Res 19:6209-6214.
13. Jennerwein MM, Eastman A, and Khokhar A (1989) Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. Chem-Biol Interact 70:39-49.
14. Kalinowski DP, Illenye S, and Van Houten B (1992) Analysis of DNA damage and repair in murine leukemia L1210 cells using a quantitative polymerase chain reaction assay. Nucleic Acids Res 20:3485-3494.
15. Kelland LR (1993) New platinum antitumor complexes. Crit Rev Oncol Hematol 15:191-219.
16. Kelland LR and McKeage MJ (1994) New platinum agents: a comparison in ovarian cancer. Drugs Aging 5:85-95.
17. LeDoux SP, Wilson GL, Beecham EJ, Stevnsner T, Wassermann K, and Bohr VA (1992) Repair of mitochondrial DNA after various types of DNA damage in Chinese hamster ovary cells. Carcinogenesis 13:1967-73.
18. Luo F, Holmes J, and Chaney SG (1997) In vitro partitioning and biotransformations of oxaliplatin in rat blood and RPMI-1640 medium. Proc Am Assoc Cancer Res 38:311.
19. Mathe G, Kidani Y, Segiguchi M, Eriguchi M, Fredj G, Peytavin G, Misset JL, Brienza S, de Vassals F, Chenu E, and Bourut C (1989) Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 43:237-250.
20. Murata T, Hibasami H, Maekawa S, Tagawa T, and Nakashima K (1990) Preferential binding of cisplatin to mitochondrial DNA and suppression of ATP generation in human malignant melanoma cells. Biochem Int 20:949-55.
21. Olivero OA, Chang PK, Lopez-Larraza DM, Semino-Mora MC, and Poirier MC (1997) Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA. Mutat Res 391:79-86.
22. Olivero OA, Semino C, Kassim A, Lopez-Larraza DM, and Poirier MC (1995) Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. Mutat Res 346:221-30.
23. Oshita F, Arioka H, Heike Y, Shiraishi J, and Saijo N (1995) Correlation of genespecific damage with cisplatin between human adenocarcinoma cells and peripheral blood mononuclear cells analyzed by polymerase chain reaction-stop assay. Jpn J Cancer Res 86:233-238.
24. Oshita F and Saijo N (1994) Rapid polymerase chain reaction assay to detect variation in the extent of gene-specific damage between cisplatin- or VP-16-resistant and sensitive lung cancer cell lines. Jpn J Cancer Res 85:669-73.
25. Pendyala L and Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53:5970-5976.
26. Pendyala L, Kidani Y, Perez R, Wilkes J, Bernacki RJ, and Creaven PJ (1995) Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett 97:177-184.
27. Plooy AC, Fichtinger-Schepman AM, Schutte HH, van Dijk M, and Lohman PH (1985) The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques. Carcinogenesis 6:561-566.
28. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, and Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865.
29. Saris CP, Van de Vaart PJM, Rietbroek RC, and Blommaert FA (1996) In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 17:2763-2769.
30. Takahara PM, Rosenzweig AC, Frederick CA, and Lippard SJ (1995) Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature (Lond) 377:649-652.
31. Tashiro T, Kawada Y, Sakurai Y, and Kidani Y (1989) Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum(II): new experimental data. Biomed Pharmacother 43:251-260.
32. Weiss RB and Christian MC (1993) New cisplatin analogues in development: a review. Drugs 46:360-377.
33. Woynarowski JM, McHugh M, Gawron LS, and Beerman TA (1995) Effects of bizelesin (U-77779), bifunctional alkylating minor groove binder, on genomic and Simian virus 40 DNA: specific damage to AT rich regions. Biochemistry 34:13042-13050.
34. Woynarowski JM, Napier C, Koester S, Chen S-F, Troyer D, Chapman W, and MacDonald JR (1997) Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene, 6-hydroxymethyl-acylfulvene (HMAF, MGI 114). Biochem Pharmacol 54:1181-1193.
35. Zsido TJ, Woynarowski JM, Baker RM, Gawron LS, and Beerman TA (1991) Induction of heat-labile sites in DNA of mammalian cells by the antitumor alkylating drug CC-1065. Biochemistry 30:3733-3738.